Completed PHASE3 NCT00044291

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Sponsor: Intarcia Therapeutics

Conditions Breast Neoplasms Neoplasms, Hormone-dependent

Interventions antiestrogen therapy aromatase inhibition atamestane endocrine therapy hormone therapy letrozole toremifene

Updated 6 times since 2017 Last updated: Jul 29, 2015 Started: Jun 30, 2002 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

Listed as NCT00044291, this PHASE3 trial focuses on Breast Neoplasms and Neoplasms, Hormone-dependent and remains completed. Sponsored by Intarcia Therapeutics, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Intarcia Therapeutics

Data source: Intarcia Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Baltimore, United States , Cherkassy, Ukraine , Columbus, United States , Dnipro, Ukraine , Donetsk, Ukraine , Great Falls, United States , Greenbrae, United States , Houston, United States , Ivano-Frankivsk, Ukraine and 37 more locations